The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
The US Food and Drug Administration (FDA) has approved Amgen's Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) for the treatment of specific rare diseases.
Credit: Melnikov Dmitriy / Shutterstock.com. The US Food and Drug Administration (FDA) has approved Amgen‘s Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) for ...
【プレスリリース】発表日:2024年05月31日ゾルベツキシマブ FDAが承認再申請を受理- 承認された場合、米国でファーストインクラスの抗CLDN18.2モノクローナル抗体となる可能性あり -アステラス製薬株式会社(本社 : ...
The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi for mantel cell lymphoma. The agency has delay a decision on Dupixent in ...
the FDA said. had small cell lung cancer. After chemotherapy and immunotherapy, with her cancer still spreading rapidly, she was accepted into the Amgen study and began getting infusions of the ...
(Reuters) -The U.S. Food and Drug Administration approved on Tuesday Amgen’s Bkemv, the first biosimilar to AstraZeneca’s rare blood disorder ... atypical hemolytic uremic syndrome – can cause anemia ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...